L P Voruganti

Summary

Affiliation: McMaster University
Country: Canada

Publications

  1. ncbi Dysglycemia in a community sample of people treated for schizophrenia: the Diabetes in Schizophrenia in Central-South Ontario (DiSCO) study
    L P Voruganti
    Department of Psychiatry and Behavioural Neurosciences, 100 West 5th Street, Hamilton, Ontario Canada L8N 3K7
    Schizophr Res 96:215-22. 2007
  2. ncbi Brain imaging research on subjective responses to psychotropic drugs
    L P Voruganti
    McMaster University, Hamilton, ON, Canada
    Acta Psychiatr Scand Suppl . 2005
  3. doi New generation antipsychotic drugs and compliance behaviour
    Lakshmi P Voruganti
    McMaster University, Hamilton, Ontario, Canada
    Curr Opin Psychiatry 21:133-9. 2008
  4. ncbi Cognition, functioning and quality of life in schizophrenia treatment: results of a one-year randomized controlled trial of olanzapine and quetiapine
    L P Voruganti
    McMaster University, Canada
    Schizophr Res 96:146-55. 2007
  5. ncbi Subjective and behavioural consequences of striatal dopamine depletion in schizophrenia--findings from an in vivo SPECT study
    Lakshmi N P Voruganti
    Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, and Humber River Regional Hospital, Toronto, Ontario, Canada
    Schizophr Res 88:179-86. 2006
  6. ncbi Impact of atypical antipsychotics on quality of life in patients with schizophrenia
    A George Awad
    Institute of Medical Science and Department of Psychiatry, University of Toronto, Humber River Regional Hospital, Toronto, Ontario, Canada
    CNS Drugs 18:877-93. 2004
  7. ncbi Going beyond: an adventure- and recreation-based group intervention promotes well-being and weight loss in schizophrenia
    Lakshmi N P Voruganti
    St Joseph s Healthcare, Hamilton, Ontario
    Can J Psychiatry 51:575-80. 2006
  8. ncbi Personal evaluation of transitions in treatment (PETiT):a scale to measure subjective aspects of antipsychotic drug therapy in schizophrenia
    Lakshmi N P Voruganti
    Institute of Medical Science, University of Toronto, Toronto, Canada
    Schizophr Res 56:37-46. 2002
  9. ncbi The burden of schizophrenia on caregivers: a review
    A George Awad
    Department of Psychiatry and the Institute of Medical Science, University of Toronto, Humber River Regional Hospital, Toronto, Ontario, M6M 3Z4, Canada
    Pharmacoeconomics 26:149-62. 2008
  10. ncbi New antipsychotics, compliance, quality of life, and subjective tolerability--are patients better off?
    A George Awad
    University of Toronto, Institute of Medical Science, Ontario
    Can J Psychiatry 49:297-302. 2004

Collaborators

Detail Information

Publications12

  1. ncbi Dysglycemia in a community sample of people treated for schizophrenia: the Diabetes in Schizophrenia in Central-South Ontario (DiSCO) study
    L P Voruganti
    Department of Psychiatry and Behavioural Neurosciences, 100 West 5th Street, Hamilton, Ontario Canada L8N 3K7
    Schizophr Res 96:215-22. 2007
    ..Discerning the modifiable risk factors is crucial for developing diabetes prevention strategies in schizophrenia...
  2. ncbi Brain imaging research on subjective responses to psychotropic drugs
    L P Voruganti
    McMaster University, Hamilton, ON, Canada
    Acta Psychiatr Scand Suppl . 2005
    ..Neuroimaging studies on subjective responses to psychotropic drugs in humans were reviewed to examine progress in the field and identify gaps in knowledge...
  3. doi New generation antipsychotic drugs and compliance behaviour
    Lakshmi P Voruganti
    McMaster University, Hamilton, Ontario, Canada
    Curr Opin Psychiatry 21:133-9. 2008
    ....
  4. ncbi Cognition, functioning and quality of life in schizophrenia treatment: results of a one-year randomized controlled trial of olanzapine and quetiapine
    L P Voruganti
    McMaster University, Canada
    Schizophr Res 96:146-55. 2007
    ..Cognitive deficits are recognized as a critical determinant of functional outcomes in schizophrenia; and second generation antipsychotic drugs have been touted for their potential to enhance cognitive functioning and community tenure...
  5. ncbi Subjective and behavioural consequences of striatal dopamine depletion in schizophrenia--findings from an in vivo SPECT study
    Lakshmi N P Voruganti
    Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, and Humber River Regional Hospital, Toronto, Ontario, Canada
    Schizophr Res 88:179-86. 2006
    ....
  6. ncbi Impact of atypical antipsychotics on quality of life in patients with schizophrenia
    A George Awad
    Institute of Medical Science and Department of Psychiatry, University of Toronto, Humber River Regional Hospital, Toronto, Ontario, Canada
    CNS Drugs 18:877-93. 2004
    ....
  7. ncbi Going beyond: an adventure- and recreation-based group intervention promotes well-being and weight loss in schizophrenia
    Lakshmi N P Voruganti
    St Joseph s Healthcare, Hamilton, Ontario
    Can J Psychiatry 51:575-80. 2006
    ..To undertake a preliminary study to assess the feasibility of clinical implementation and evaluate the effectiveness of a novel adventure- and recreation-based group intervention in the rehabilitation of individuals with schizophrenia...
  8. ncbi Personal evaluation of transitions in treatment (PETiT):a scale to measure subjective aspects of antipsychotic drug therapy in schizophrenia
    Lakshmi N P Voruganti
    Institute of Medical Science, University of Toronto, Toronto, Canada
    Schizophr Res 56:37-46. 2002
    ....
  9. ncbi The burden of schizophrenia on caregivers: a review
    A George Awad
    Department of Psychiatry and the Institute of Medical Science, University of Toronto, Humber River Regional Hospital, Toronto, Ontario, M6M 3Z4, Canada
    Pharmacoeconomics 26:149-62. 2008
    ....
  10. ncbi New antipsychotics, compliance, quality of life, and subjective tolerability--are patients better off?
    A George Awad
    University of Toronto, Institute of Medical Science, Ontario
    Can J Psychiatry 49:297-302. 2004
    ..This overview reviews the impact of second-generation antipsychotics on less frequently researched outcomes such as medication-adherence behaviour, quality of life, and subjective tolerability in patients with schizophrenia...
  11. ncbi Body weight, image and self-esteem evaluation questionnaire: development and validation of a new scale
    A George Awad
    Department of Psychiatry, Humber Regional Hospital, 1575 Keele Street, Toronto M6M 3Z4, Canada
    Schizophr Res 70:63-7. 2004
    ....
  12. pmc What's in a name? The evolution of the nomenclature of antipsychotic drugs
    Caroline King
    Department of Psychiatry, University of Western Ontario, London, Ont
    J Psychiatry Neurosci 27:168-75. 2002
    ..This article examines the origins, progenitors and usage of the word "antipsychotic" and explores its ramifications...